Correlation Engine 2.0
Clear Search sequence regions

  • acinar cells (1)
  • cancer (1)
  • disease and (1)
  • dyslipidemia (1)
  • factors x (1)
  • female (1)
  • Ferritins (2)
  • fistula (1)
  • humans (1)
  • hyperlipidemias (1)
  • liver (1)
  • liver disease (1)
  • male (2)
  • obesity (3)
  • pancreas (7)
  • patients (1)
  • period (1)
  • research (1)
  • risk factors (2)
  • Sizes of these terms reflect their relevance to your search.

    After the first description of fatty pancreas in 1933, the effects of pancreatic steatosis have been poorly investigated, compared with that of the liver. However, the interest of research is increasing. Fat accumulation, associated with obesity and the metabolic syndrome (MetS), has been defined as "fatty infiltration" or "nonalcoholic fatty pancreas disease" (NAFPD). The term "fatty replacement" describes a distinct phenomenon characterized by death of acinar cells and replacement by adipose tissue. Risk factors for developing NAFPD include obesity, increasing age, male sex, hypertension, dyslipidemia, alcohol and hyperferritinemia. Increasing evidence support the role of pancreatic fat in the development of type 2 diabetes mellitus, MetS, atherosclerosis, severe acute pancreatitis and even pancreatic cancer. Evidence exists that fatty pancreas could be used as the initial indicator of "ectopic fat deposition", which is a key element of nonalcoholic fatty liver disease and/or MetS. Moreover, in patients with fatty pancreas, pancreaticoduodenectomy is associated with an increased risk of intraoperative blood loss and post-operative pancreatic fistula.


    Roberto Catanzaro, Biagio Cuffari, Angelo Italia, Francesco Marotta. Exploring the metabolic syndrome: Nonalcoholic fatty pancreas disease. World journal of gastroenterology. 2016 Sep 14;22(34):7660-75

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 27678349

    View Full Text